Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone,Inapplicable
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Kamada
Deal Size : Undisclosed
Deal Type : Agreement
AcuCort Signs Its First Commercial Agreement for The Company's Drug Zeqmelit™
Details : Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit™ (dexamethasone) in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.
Product Name : Zeqmelit
Product Type : Steroid
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Dexamethasone,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Kamada
Deal Size : Undisclosed
Deal Type : Agreement